Used primarily in the synthesis of pharmaceutical agents, particularly as an intermediate in the production of targeted protein degraders such as cereblon E3 ligase modulators. It plays a key role in the development of oncology therapeutics, especially in drugs designed to treat hematological cancers like multiple myeloma and myelodysplastic syndromes. Its structure enables selective binding to cereblon, facilitating the degradation of disease-causing proteins. This compound is also utilized in research settings to explore new immunomodulatory and anti-inflammatory agents.